MX375557B - Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer. - Google Patents
Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.Info
- Publication number
- MX375557B MX375557B MX2017000840A MX2017000840A MX375557B MX 375557 B MX375557 B MX 375557B MX 2017000840 A MX2017000840 A MX 2017000840A MX 2017000840 A MX2017000840 A MX 2017000840A MX 375557 B MX375557 B MX 375557B
- Authority
- MX
- Mexico
- Prior art keywords
- aflibercept
- outcome
- predicting
- suffer
- cancer
- Prior art date
Links
- 108010081667 aflibercept Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 229960002833 aflibercept Drugs 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102000004890 Interleukin-8 Human genes 0.000 abstract 2
- 108090001007 Interleukin-8 Proteins 0.000 abstract 2
- 229940096397 interleukin-8 Drugs 0.000 abstract 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 1
- 229960002760 ziv-aflibercept Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5421—IL-8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al uso de interleuquina-8 (lL-8) como un biomarcador para predecir el resultado del tratamiento con aflibercept, o ziv-aflibercept de un paciente que se sospecha que padece un cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306172 | 2014-07-18 | ||
| PCT/EP2015/066262 WO2016008975A1 (en) | 2014-07-18 | 2015-07-16 | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017000840A MX2017000840A (es) | 2017-05-04 |
| MX375557B true MX375557B (es) | 2025-03-06 |
Family
ID=51220534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000840A MX375557B (es) | 2014-07-18 | 2015-07-16 | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10501523B2 (es) |
| EP (1) | EP3170005B1 (es) |
| JP (1) | JP6685276B2 (es) |
| KR (1) | KR102486321B1 (es) |
| CN (1) | CN107076750B (es) |
| AU (1) | AU2015289124B2 (es) |
| CY (1) | CY1122233T1 (es) |
| DK (1) | DK3170005T3 (es) |
| EA (1) | EA035674B1 (es) |
| ES (1) | ES2732925T3 (es) |
| HR (1) | HRP20191145T1 (es) |
| HU (1) | HUE043951T2 (es) |
| IL (1) | IL250110B (es) |
| LT (1) | LT3170005T (es) |
| MA (1) | MA40354A (es) |
| MX (1) | MX375557B (es) |
| PL (1) | PL3170005T3 (es) |
| PT (1) | PT3170005T (es) |
| RS (1) | RS58957B1 (es) |
| SG (1) | SG11201700284UA (es) |
| SI (1) | SI3170005T1 (es) |
| TR (1) | TR201909951T4 (es) |
| TW (1) | TWI705247B (es) |
| WO (1) | WO2016008975A1 (es) |
| ZA (1) | ZA201700371B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2732925T3 (es) | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EA037406B1 (ru) * | 2016-01-25 | 2021-03-25 | Санофи | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови |
| CN107602702A (zh) | 2017-09-22 | 2018-01-19 | 生标（上海）医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| KR20210021299A (ko) | 2018-05-10 | 2021-02-25 | 리제너론 파아마슈티컬스, 인크. | 고농도 vegf 수용체 융합 단백질 함유 제제 |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| KR102720956B1 (ko) * | 2020-12-15 | 2024-10-24 | 삼천당제약주식회사 | 안과용 제형을 포함하는 시린지 |
| WO2023153535A1 (ko) * | 2022-02-09 | 2023-08-17 | 삼천당제약주식회사 | 안과용 제형을 포함하는 시린지 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| WO1993022336A1 (en) | 1992-04-30 | 1993-11-11 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor viii complex |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| ATE281469T1 (de) | 1993-03-25 | 2004-11-15 | Merck & Co Inc | Inhibitor des wachstumsfaktors für gefäss- endothelzellen |
| US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| GB9410533D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
| TW438775B (en) | 1995-04-07 | 2001-06-07 | Pharmacia & Upjohn Co Llc | Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| CA2266419A1 (en) | 1996-09-24 | 1998-04-02 | Merck & Co., Inc. | Gene therapy for inhibition of angiogenesis |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| DE19724793A1 (de) | 1997-06-06 | 1998-12-10 | Schering Ag | D-mutierte Peptide mit VEGF-Rezeptor blockierenden Eigenschaften |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| JPH1180024A (ja) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| DE19841985A1 (de) | 1998-09-03 | 2000-03-09 | Schering Ag | Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
| AP1243A (en) | 1999-02-01 | 2004-02-02 | Servier Lab | Core tablet for controlled release of gliclazide after oral administration. |
| WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| CA2376379C (en) | 1999-06-08 | 2007-08-07 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| DE19938724A1 (de) | 1999-08-16 | 2001-02-22 | Tetra Laval Holdings & Finance | Vorrichtung zur Herstellung von Kunststoffbehältern mittels Streckblasformen |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
| GT200100079A (es) | 2000-05-10 | 2001-12-31 | Metodo para regular la angiogenesis utilizando proteina ryk | |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| US20030092019A1 (en) | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| US20040023864A1 (en) | 2001-05-09 | 2004-02-05 | Steve Roczniak | Method of regulating angiogenesis using ryk protein |
| CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| DE60314378T2 (de) | 2002-03-01 | 2008-02-28 | Pfizer Italia S.R.L. | Kristalline polymorphe form von irinotecanhydrochlorid |
| JP2004006671A (ja) | 2002-03-22 | 2004-01-08 | Sanyo Electric Co Ltd | 電荷結合素子およびその製造方法 |
| AU2004226417B2 (en) | 2003-03-28 | 2009-01-22 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking VEGF-mediated activity |
| DK2335725T3 (en) | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
| US7300654B2 (en) | 2003-05-28 | 2007-11-27 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection in high risk keratoplasty patients |
| AU2004242586C1 (en) | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
| US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US20050112061A1 (en) | 2003-08-06 | 2005-05-26 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
| US20050196340A1 (en) | 2003-08-06 | 2005-09-08 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
| SI1660057T1 (sl) | 2003-08-27 | 2012-10-30 | Ophthotech Corp | Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti |
| DE60326353D1 (de) | 2003-11-06 | 2009-04-09 | Nestle Waters Man & Technology | Herstellungsverfahren von Behältern aus Polyesterharz |
| US7582726B2 (en) | 2003-11-10 | 2009-09-01 | Ghc Research Development Corporation | VEGF receptor antagonists |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| US7354580B2 (en) | 2004-06-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
| AU2005265071A1 (en) | 2004-06-18 | 2006-01-26 | Memorial Sloan-Kettering Cancer Center | VEGF inhibitors for the treatment of malignant pleural effusion |
| US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| EP2324848A3 (en) | 2004-10-21 | 2011-09-14 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| FR2878749B1 (fr) | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
| AU2006214658A1 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| AU2006213856B2 (en) | 2005-02-11 | 2011-03-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent |
| EP1855708A1 (en) | 2005-03-11 | 2007-11-21 | Regeneron Pharmaceuticals, Inc. | Treating anemia by inhibition of vegf |
| CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| RU2414924C2 (ru) | 2005-08-12 | 2011-03-27 | Ридженерон Фармасьютикалз, Инк. | Способы лечения заболеваний антагонистами vegf |
| US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
| RU2432155C3 (ru) | 2006-06-16 | 2017-11-17 | Ридженерон Фармасьютикалз, Инк. | Составы антагониста vegf, подходящие для интравитреального введения |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| EP2136630A4 (en) * | 2007-03-23 | 2010-06-02 | Precision Therapeutics Inc | METHODS FOR ASSESSING ANGIOGENIC POTENTIAL IN CULTURE |
| FR2918279B1 (fr) | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| RS54847B2 (sr) | 2007-10-04 | 2019-09-30 | Onyx Therapeutics Inc | Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto-epoksida |
| US20090170925A1 (en) * | 2007-10-29 | 2009-07-02 | Eisai R&D Management Co., Ltd. | Methods for prognosing the ability of a zearalenone analog compound to treat cancer |
| ES2372236T3 (es) | 2007-11-30 | 2012-01-17 | Genentech, Inc. | Polimorfismos de vegf y terapia anti-angiogénesis. |
| EP2143542A1 (fr) | 2008-07-07 | 2010-01-13 | Nestec S.A. | Procédé et dispositif de conditionnement d'un liquide alimentaire |
| FR2933702A1 (fr) | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| WO2010022201A2 (en) | 2008-08-22 | 2010-02-25 | Osteogenex Inc. | Folinic acid derivatives for promoting bone growth |
| WO2010042903A1 (en) | 2008-10-09 | 2010-04-15 | Alfagene Bioscience, Inc | Use and identification of biomarkers for gastrointestinal diseases |
| EP2540843B1 (en) | 2008-11-05 | 2014-07-02 | Genentech, Inc. | Genetic polymorphisms in age-related macular degeneration |
| CN102325549A (zh) | 2009-03-31 | 2012-01-18 | 罗氏格黎卡特股份公司 | 用人源化抗-EGFR IgG1抗体和伊立替康治疗癌症 |
| WO2010124264A2 (en) | 2009-04-24 | 2010-10-28 | University Of Southern California | Genetic variants in angiogenesis pathway associated with clinical outcome |
| KR20120106935A (ko) * | 2009-07-13 | 2012-09-27 | 제넨테크, 인크. | 암의 치료를 위한 진단 방법 및 조성물 |
| AU2010278853B2 (en) | 2009-07-31 | 2014-05-15 | Amcor Rigid Plastics Usa, Llc | Hot-fill container |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| BR112012007555B1 (pt) * | 2009-10-02 | 2020-09-29 | Cylene Pharmaceuticals, Inc | Métodos in vitro para prever a sensibilidade e resposta de doenças mediadas por proteína quinase ck2 a inibidores de ck2 |
| EP2517708A4 (en) * | 2009-12-25 | 2013-07-03 | Taiho Pharmaceutical Co Ltd | Method for predicting therapeutic effect of chemotherapy on hepatocellular carcinoma patient |
| DK2829881T3 (en) * | 2010-07-14 | 2017-12-04 | Vision Tech Bio Pty Ltd | Colorectal cancer diagnostic |
| AR085301A1 (es) | 2011-02-23 | 2013-09-18 | Sanofi Sa | Polimorfismos de un solo nucleotido en el promotor del gen vegfa y su uso como marcadores predictivos para tratamientos anti-vegf |
| TWI838039B (zh) * | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US9945862B2 (en) * | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2013138790A1 (en) * | 2012-03-15 | 2013-09-19 | Research Foundation Of State University Of New York | Combination therapies including inhibitors of the extracellular domain of e-cadherin |
| JP6019790B2 (ja) | 2012-06-19 | 2016-11-02 | 富士電機株式会社 | 接合方法及び接合部材 |
| HK1206628A1 (en) | 2012-08-02 | 2016-01-15 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
| ES2732925T3 (es) | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
| EA037406B1 (ru) | 2016-01-25 | 2021-03-25 | Санофи | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови |
-
2015
- 2015-07-16 ES ES15738625T patent/ES2732925T3/es active Active
- 2015-07-16 SG SG11201700284UA patent/SG11201700284UA/en unknown
- 2015-07-16 HR HRP20191145TT patent/HRP20191145T1/hr unknown
- 2015-07-16 EP EP15738625.1A patent/EP3170005B1/en active Active
- 2015-07-16 PL PL15738625T patent/PL3170005T3/pl unknown
- 2015-07-16 RS RS20190796A patent/RS58957B1/sr unknown
- 2015-07-16 AU AU2015289124A patent/AU2015289124B2/en active Active
- 2015-07-16 MA MA040354A patent/MA40354A/fr unknown
- 2015-07-16 KR KR1020177004155A patent/KR102486321B1/ko active Active
- 2015-07-16 EA EA201790211A patent/EA035674B1/ru not_active IP Right Cessation
- 2015-07-16 CN CN201580050366.2A patent/CN107076750B/zh active Active
- 2015-07-16 PT PT15738625T patent/PT3170005T/pt unknown
- 2015-07-16 SI SI201530796T patent/SI3170005T1/sl unknown
- 2015-07-16 MX MX2017000840A patent/MX375557B/es active IP Right Grant
- 2015-07-16 DK DK15738625.1T patent/DK3170005T3/da active
- 2015-07-16 LT LTEP15738625.1T patent/LT3170005T/lt unknown
- 2015-07-16 HU HUE15738625A patent/HUE043951T2/hu unknown
- 2015-07-16 WO PCT/EP2015/066262 patent/WO2016008975A1/en not_active Ceased
- 2015-07-16 TR TR2019/09951T patent/TR201909951T4/tr unknown
- 2015-07-16 JP JP2017502806A patent/JP6685276B2/ja active Active
- 2015-07-17 TW TW104123366A patent/TWI705247B/zh active
-
2017
- 2017-01-15 IL IL250110A patent/IL250110B/en active IP Right Grant
- 2017-01-17 ZA ZA2017/00371A patent/ZA201700371B/en unknown
- 2017-01-18 US US15/408,827 patent/US10501523B2/en active Active
-
2019
- 2019-07-10 CY CY20191100736T patent/CY1122233T1/el unknown
- 2019-10-24 US US16/663,000 patent/US11208461B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375557B (es) | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer. | |
| MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
| MX375467B (es) | Proceso para la preparacion de un compuesto de diariltiohidantoina. | |
| LT3556775T (lt) | Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui | |
| PH12016501763A1 (en) | Multispecific antibodies | |
| EP3194624A4 (en) | Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor | |
| ZA201703510B (en) | Antibodies, uses & methods | |
| EA201691952A1 (ru) | Композиции и методы, имеющие отношение к диагностике рака предстательной железы | |
| EP3392348A3 (en) | Method for selecting personalized tri-therapy for cancer treatment | |
| MX383748B (es) | Procesos para la preparación de un compuesto de diariltiohidantoína. | |
| SG11201609677WA (en) | Method for reducing the chlorine content of organomonophosphites using dimethylaminobutane, triethylamine or triethanolamine | |
| MX2016015163A (es) | Biomarcadores mit y metodos para su uso. | |
| LT3191514T (lt) | Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą | |
| MX384921B (es) | Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca. | |
| MA40636A (fr) | Procédés pour détecter le cancer de la prostate | |
| EA201692482A1 (ru) | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) | |
| EA201792527A1 (ru) | Лечение зуда | |
| ZA201804318B (en) | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker | |
| PH12017501872A1 (en) | Methods of treating diseases | |
| MX2016015298A (es) | Inhibidores de nampt y metodos. | |
| TH1601003417A (th) | วิธีการสำหรับการผลิตเหล็กกล้าไร้สนิมแบบดูเพล็กซ์ความแข็งแรงสูง | |
| UA82138U (ru) | Способ прогнозирования развития остеопороза после перелома | |
| UA91508U (uk) | Застосування пороху димного для лікування мікозів | |
| MY179202A (en) | Method for producing specific ?,b-unsaturated aldehydes | |
| AU2014903680A0 (en) | Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |